3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Glioblastoma
115
Gliosarcoma
53
Brain Neoplasms
53
Glioma
47
Central Nervous System Neoplasms
30
Astrocytoma
29
Melanoma
26
Oligodendroglioma
14
Neuroblastoma
10
Neoplasm Metastasis
9
Recurrence
7
Ependymoma
7
Sarcoma
6
Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Skin Neoplasms
5
Sarcoma, Ewing
5
Lymphoma
5
Breast Neoplasms
5
Spinal Cord Neoplasms
4
Somatostatinoma
4
Neuroectodermal Tumors, Primitive, Peripheral
4
Medulloblastoma
4
Colorectal Neoplasms
4
Small Cell Lung Carcinoma
3
Lung Neoplasms
3
Gastrinoma
3
Carcinoma, Islet Cell
3
Uveal Melanoma
2
Rhabdomyosarcoma
2
Interventions
fludarabine phosphate
87
Cyclophosphamide
78
Whole-Body Irradiation
59
Azacitidine
59
fludarabine
56
Mycophenolic Acid
56
Busulfan
53
Tacrolimus
51
Peripheral Blood Stem Cell Transplantation
41
Melphalan
40
Cytarabine
38
Antilymphocyte Serum
38
Filgrastim
37
Granulocyte Colony-Stimulating Factor
33
Cyclosporine
33
Methotrexate
32
Decitabine
32
thymoglobulin
22
Thiotepa
21
Clofarabine
21
Cord Blood Stem Cell Transplantation
19
Stem Cell Transplantation
16
Alemtuzumab
16
Sirolimus
15
Rituximab
15
sargramostim
12
Lenalidomide
12
Etoposide
11
Radiotherapy
10
Cyclosporins
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Myelodysplastic Syndromes
×
Temozolomide
×
Clear all
NCT00687323
2017-06-07
TALL
Merck Sharp & Dohme LLC
Phase 2
Completed
47 enrolled
12 charts